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ABSTRACT 22 
Background: Nicotine Replacement Therapy (NRT) was licensed for harm reduction in the UK in 2005, 23 
and guidance to UK Stop Smoking Services (SSS) to include long-term partial or complete substitution of 24 
cigarettes with NRT was issued in 2013. Yet, NRT prevalence data and data on changes in biomarkers 25 
associated with long-term NRT use among SSS clients are scarce. 26 
Methods: SSS clients abstinent 4 weeks post-quit date were followed up at 12 months. At baseline standard 27 
socio-demographic, smoking and SSS use characteristics were collected and of those eligible, 60.6% 28 
(1,047/1,728) provided data on smoking status and NRT use at follow-up. A subsample also provided saliva 29 
samples at baseline and of those eligible, 36.2% (258/712) provided follow-up samples. Saliva was analysed 30 
for cotinine (a metabolite of nicotine) and alpha-amylase (a stress biomarker). 31 
Results: Among those who had used NRT during their initial quit attempt (61.5%, 95%CI 58.4-64.6), 6.0% 32 
(95%CI 4.3-8.3%) were still using NRT at one year, significantly more ex-smokers than relapsed smokers 33 
(9.5% vs. 3.7%; p=0.005). In adjusted analysis, NRT use interacted with smoking status to determine change 34 
in cotinine, but not alpha-amylase, levels (Wald χ2 (1)=13.0, p<0.001): cotinine levels remained unchanged 35 
in relapsed smokers and ex-smokers with long-term NRT use but decreased in ex-smokers without long-36 
term NRT use. 37 
Conclusions: Long-term NRT use is uncommon in SSS clients, particularly among relapsed smokers. Its 38 
use is associated with continued high intake of nicotine among ex-smokers but does not increase nicotine 39 
intake in smokers. It does not appear to affect stress response. 40 
 41 
Key words: Stop Smoking Services, Nicotine Replacement Therapy, Cotinine, Harm Reduction, Alpha-42 
amylase43 
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IMPLICATIONS 44 
Little is known about the long-term effects of Nicotine Replacement Therapy (NRT). Given an 45 
increasing shift towards harm reduction in tobacco control, reducing the harm from combustible products by 46 
complete or partial substitution with non-combustible products, more data on long-term use are needed. This 47 
study shows that in the context of stop smoking services, clients rarely use products for up to a year and that 48 
NRT use does not affect users’ stress response. Ex-smokers using NRT long-term can completely replace 49 
nicotine from cigarettes with nicotine from NRT; long-term NRT use by continuing smokers does not 50 
increase nicotine intake. Long-term NRT appears to be a safe and effective way to reduce exposure to 51 
combustible nicotine.52 
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INTRODUCTION 53 
The main aim of Stop Smoking Services (SSS) is to support smokers to quit tobacco use. However, 54 
not all smokers either feel able to or want to stop smoking completely. For this reason, alternative 55 
approaches have been explored to reduce harm from smoking in this population. Harm reduction refers to 56 
the reduced psychological or physiological harm from substance use without complete cessation 1. For 57 
current smokers, harm reduction may refer to the partial substitution of cigarettes with non-combustible 58 
forms of nicotine delivery such as nicotine replacement therapy (NRT) to reduce cigarette consumption or 59 
for temporary abstinence. For ex-smokers, harm reduction constitutes the complete, long-term substitution 60 
of combustible tobacco products (e.g. cigarettes) with less harmful non-combustible nicotine delivery 61 
devices 2. There is good evidence from both population studies and clinical trials that the provision of NRT 62 
to smokers who cut down their cigarette consumption results in more sustained decreases in cigarette 63 
consumption and improves their chances to stop smoking completely 3,4. It increases motivation to stop and 64 
improves quit rates 1,3 but does not increase overall nicotine intake 5,6. Trials have also shown that extended 65 
use of NRT by ex-smokers may result in better long-term abstinence rates by reducing relapse 7,8. For these 66 
reasons, NRT has been licensed for harm reduction in the UK since 2005 9,10. Based on a previous report 11, 67 
guidance was also issued to UK Stop Smoking Services (SSS) in 2013 to include partial or complete long-68 
term substitution of cigarettes with NRT in tailored quit plans for smokers who have difficulty to stop 69 
smoking completely so as to help them reduce consumption with the eventual aim to stop smoking 12. 70 
 71 
The vast majority of the harm from smoking is caused by the burning of tobacco and not nicotine 13. 72 
Thus NRT as a substitute for cigarettes is important to study. Although the importance of e-cigarettes for 73 
harm reduction purposes cannot be doubted, NRT is likely to remain a major component of harm reduction 74 
strategies, given its long history in tobacco control and continuing NRT product innovation 14 and on-going 75 
resistance of some smokers to e-cigarettes 15. Despite being an established treatment, there is considerable 76 
worry among potential users 16 and stop-smoking advisors 17 regarding the safety of long-term NRT use, 77 
possibly due to misunderstandings about the role of nicotine separate from smoked tobacco 18. While studies 78 
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which have looked at this issue find that long-term NRT use is safe and any associated health risks small 19, 79 
certainly compared with continued smoking 20,21, most data come from clinical trials, which have samples 80 
that tend to differ in important ways from general population samples, biasing outcomes 22. Given recent 81 
calls for further research in the area of harm reduction 12, more studies on real-world use are required. 82 
 83 
A recent population-based study suggested that only a small percentage of ex-smokers continue to 84 
use NRT beyond the standard length of three months and that long-term use is associated with lower 85 
nicotine intake compared with smokers 6. However, in many industrialised countries most NRT is purchased 86 
over the counter 23, rather than coupled with specialist behavioural support, which is more effective 24. 87 
Therefore, existing findings may not generalise to smokers attending UK SSS, especially since in this 88 
context the NRT provided is either free or heavily subsidised. In light of the recent broadening in the 89 
provision of NRT in SSS, there remains a need to evaluate harm reduction with NRT in this context. 90 
 91 
This study describes the impact of longer-term NRT use among smokers who made a quit attempt 92 
with SSS support and agreed to take part in the ‘Evaluating Long Term Outcomes of NHS Stop-Smoking 93 
Services’ (ELONS) study conducted 2012-2014 25. Participants were followed up for one year and provided 94 
information on their NRT use. A subset also provided saliva samples which were analysed for two 95 
biomarkers of interest: cotinine, the primary metabolite of nicotine as a biomarker of exposure; and alpha-96 
amylase, a digestive enzyme and indicator of autonomic nervous system activation which correlates with 97 
acute and chronic stress, as a biomarker of risk/potential harm 26. We included this biomarker as animal 98 
research has shown that chronic nicotine self-administration can alter stress response in rodents 27,28. 99 
Specifically, this study aimed to answer the following research questions: 100 
 101 
1) What is the prevalence of long-term NRT use among smokers and ex-smokers who had attempted 102 
to stop smoking using SSS? 103 
2) What is the impact of long-term NRT use on biomarkers of nicotine exposure and stress among 104 
smokers and ex-smokers who had attempted to stop smoking using SSS?105 
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METHODS 106 
Study design and participants 107 
Given the aims of this study, we report only on those with baseline and follow-up data. Full details of 108 
the study design and sampling are provided elsewhere 25. Briefly, as part of the ELONS study, clients 109 
participating in English SSS who set a quit date were asked if they were interested in taking part in a long-110 
term (12 months) evaluation of the services by advisors and informed consent was obtained from all 111 
participants, resulting in a baseline sample of 3,045 clients. As per standard NHS SSS guidelines, smoking 112 
status was recorded at 4-week follow-up 29 and only those who were abstinent at 4 weeks (56.7%; 113 
1,728/3,045) were eligible for long-term follow-up. Of all eligible participants for 12 month follow-up, 114 
60.6% (1,047/1,728) could be contacted by telephone to assess smoking status and NRT use, thus providing 115 
complete baseline and follow-up questionnaire data (see Table 1 for participant details). Of those 116 
contactable, 53.3% (558/1,047) self-reported as abstinent and were eligible for a home visit to verify their 117 
smoking status, of whom 4.6% (26/558) failed CO-verification and were therefore reclassified as smokers 118 
for the purposes of this analysis. The 12-month follow-up started in April 2013 and finished in March 2014. 119 
 120 
A subsample of participants also provided a saliva sample at baseline, before their target quit date 121 
(61.6%; 1,875/3,045). Of those who were eligible to provide a saliva sample at follow-up (i.e. successful 122 
quitters at four weeks with a baseline saliva sample who self-reported abstinence at 12-month follow-up and 123 
therefore had a home visit), 52.8% (169/320) provided a sample. Because relapsers did not have a home visit 124 
(and therefore were not asked to provide a saliva sample), an additional random selection of participants 125 
with baseline saliva samples who had relapsed at 4-week follow-up were contacted at 12 months (83.4%, 126 
392/470) to obtain follow-up saliva samples from smokers. Participants were sent a saliva kit through the 127 
post and asked to return samples directly to UCL. The saliva kit contained two Sarstedt Salivettes®, a letter 128 
from the Principal Investigator asking for their help, detailed instructions on sample collection and a £10 129 
shopping voucher. Of those approached, 22.6% (89/392) returned a saliva sample, resulting in an overall 130 
response rate from face-to-face or postal collection of 36.2% (258/712) with complete baseline and follow-131 
up biomarker data (see Table 1 for participant details). 132 
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 133 
Measures 134 
Questionnaire items 135 
In addition to standard questions on smoking and socio-demographic characteristics, a number of 136 
items were included in the baseline questionnaire to help evaluate UK SSS (see 25. Advisors recorded the 137 
types of pharmacotherapy and behavioural intervention used during the quit attempt. It should be noted that 138 
at the time of the study, e-cigarettes (another harm reduction tool) were only just becoming popular and 139 
client use was not routinely recorded by SSS. At 12-month follow-up, questions related to long-term NRT 140 
use were also assessed retrospectively: participants were asked to indicate whether they had used NRT for 141 
their initial quit attempt and, if so, how long they had used NRT for, and if they were still using NRT now. 142 
As the use of other nicotine-containing products (including e-cigarettes) was not assessed at baseline, this 143 
was assessed at follow-up only. In order to ascertain smoking status and use of NRT in those participants 144 
who provided a saliva sample through the post and did not receive a home visit, these respondents were 145 
asked to indicate on a tick box included on the salivettes whether they were currently smoking (yes/no) and 146 
used NRT or e-cigarettes (yes/no). 147 
 148 
Biomarkers 149 
Saliva samples were collected with Sarstedt Salivettes® and stored in -20°C freezers, ready for 150 
analysis. Saliva was analysed for cotinine by ABS laboratory using rapid liquid-gas chromatograpy 30 and 151 
for alpha-amylase activity by Salimetrics laboratory using an established enzyme-kinetic methodology 31. 152 
Although alpha-amylase activity is largely independent of flow-rate 32, all participants were instructed to 153 
keep the salivettes in the mouth for the same amount of time (1-2 minutes) without chewing as per 154 
recommendation 33. In addition, all participants were asked to abstain from drinking or eating immediately 155 
before providing a sample. Whilst alpha-amylase exhibits a diurnal pattern, it remains relatively stable 156 
throughout the day following a rise in the first hours after waking 34. Participants were therefore instructed to 157 
provide two samples during waking hours, approximately ten minutes apart to increase reliability of 158 
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measurement (the average coefficient of variation in alpha-amylase activity at baseline was 1.7% and at 159 
follow-up 1.8%). 160 
 161 
Analysis 162 
Data were analysed with IBM SPSS Statistics 20.0.0. Comparisons were made between those who 163 
did and did not have complete baseline and follow-up data for questionnaire items (to assess NRT 164 
prevalence) and those who did or did not have complete baseline and follow-up biomarker data (to assess 165 
impact). Differences were assessed with χ2-tests and independent t-tests for categorical and continuous 166 
variables, respectively. In the prevalence analysis, descriptive statistics including 95% confidence intervals 167 
(95%CI) were calculated and, where applicable, groups compared using logistic regression. To correct for 168 
non-response all prevalence estimates are weighted (see 25). 169 
 170 
In the biomarker analysis, due to the typically positively skewed distribution of cotinine and alpha-171 
amylase values and relatively small sample size, geometric means and interquartile ranges were calculated. 172 
The non-parametric Kruskal-Wallis and Wilcoxon tests were used to assess between-group differences and 173 
within-group differences (to look at change across time), respectively. In sensitivity analysis, findings were 174 
re-examined with generalized linear models for between- and within-group comparisons that used a gamma 175 
distribution with a log link (all zero values were replaced with 0.001) to account for the non-normal 176 
distribution and adjusted for potential confounders (age, sex, ethnicity, occupation, any medical condition 177 
and nicotine dependence). Statistical significance was set at the standard level (p<0.05), and the Bonferroni 178 
correction was applied to account for multiple comparisons and Type I error rate. The study received ethical 179 
approval from the South East Scotland Research Ethics Committee (11/AL/0256) and was carried out in 180 
accordance with the ethical principles on human research, as set out in the Declaration of Helsinki. 181 
182 
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RESULTS 183 
Prevalence of long-term NRT use among current smokers and ex-smokers 184 
Information on long-term NRT use was provided by 1,047 participants (34.4% of the total ELONS 185 
sample) who constitute the analytic sample for the prevalence analysis. Those who were lost at follow-up 186 
were younger, had smoked for a shorter period, were less likely to have a medical condition, to be white or 187 
cohabiting (Table 1). All prevalence estimates in this section are weighted. 188 
 189 
Of clients followed-up, 61.5% (95%CI 58.4-64.6, N=583) reported using NRT during their initial 190 
quit attempt. This figure was somewhat higher than the recorded NRT use in SSS (around N=500 when 191 
including the ‘Other’ category in Table 1), suggesting that some participants had obtained additional NRT 192 
over the counter. Figure 1A provides a breakdown of clients in terms of the length of use of NRT and as a 193 
function of smoking status at follow-up. As can be seen, most clients who started on NRT used it for at least 194 
eight weeks and more than one in five (21.5%, 95%CI 18.3-25.0, N=137) for longer than the standard 12 195 
weeks. However, long-term use was relatively rare with less than one in ten participants still using non-196 
combustible nicotine delivery devices at 12-month follow-up (8.4%, 95%CI 6.4-11.0, N=50), including both 197 
NRT and e-cigarettes. In this sample, NRT use was twice as prevalent (6.0%, 95%CI 4.3-8.3%, N=35) as 198 
use of e-cigarettes at 12 months (2.9%, 1.8-4.7%, N=18; some participants were dual product users). 199 
 200 
Generally, the pattern of NRT use across the study period was relatively similar for those who had 201 
remained abstinent and those who had relapsed by 12-month follow-up (Figure 1A). However, ex-smokers 202 
had higher rates of NRT use compared with relapsers at all time-points. At 12-month follow-up, long-term 203 
ex-smokers were over four-times more likely than relapsers to be still using non-combustible nicotine 204 
delivery devices (OR 4.25, 95%CI 2.15-8.40, p<0.001): 14.0% (95%10.3-18.7, N=38) of ex-smokers were 205 
still using these compared with 3.7% (95%CI 2.0-6.5, N=12) of relapsers. This difference, while being 206 
attenuated, remained significant when excluding those who used e-cigarettes only (OR 2.91, 95%CI 1.38-207 
6.11, p=0.005) with 9.5% (95% 6.4-13.8, N=25) of ex-smokers and 3.5% (95%CI 1.9-6.3, N=10) of 208 
relapsers still using NRT, respectively. Comparing the quitters and relapsers who were or were not using 209 
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NRT at follow-up in terms of the characteristics presented in Table 1 showed that dependence was the only 210 
variable (other than medication use, as would be expected) that differed between groups (F(3, 1037)=5.52, 211 
p<0.001). Relapsers without NRT use had significantly higher dependence scores than quitters, irrespective 212 
of their NRT use. 213 
 214 
When looking at individual nicotine-delivery devices still used at 12-month follow-up, e-cigarettes 215 
were the most popular, followed by the nicotine lozenge, patch and gum (Figure 1B). No-one used the nasal 216 
spray, possibly due to the higher cost of the nasal spray compared with other NRT products, and 16.8% were 217 
using multiple products. Due to the small numbers involved, there was insufficient power to detect 218 
meaningful differences between those who had remained abstinent and those who had relapsed. 219 
 220 
Impact of long-term NRT use on biomarkers of nicotine exposure and stress among current smokers 221 
and ex-smokers 222 
Baseline and follow-up saliva samples were provided by 258 participants (8.5% of the total sample) 223 
who constitute the analytic sample for the biomarker analysis. Those lost to follow-up were younger, less 224 
likely to be cohabiting and there were some differences in the treatments used; they were also more 225 
dependent (Table 1). 226 
 227 
There were no differences in baseline cotinine levels between any of the groups (Table 2). This was 228 
confirmed in adjusted analysis controlling for potential confounders which showed that older age (Wald χ2 229 
(1)= 6.6, p=0.011) and greater dependence (Wald χ2 (1)=26.7, p<0.001) were the only significant predictors 230 
of baseline cotinine levels. Similarly, there were no group differences in baseline alpha-amylase levels, 231 
again confirmed in adjusted analysis (Table 2). This showed that older age (Wald χ2 (1)=10.6, p=0.001), 232 
being non-white (Wald χ2 (1)=5.3, p=0.022) and having any medical condition (Wald χ2 (1)=9.8, p=0.002) 233 
were associated with higher alpha-amylase activity at baseline. 234 
 235 
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At follow-up, there was a clear difference between groups in cotinine levels (Kruskal Wallis H 236 
(3)=130.2, p<0.001). Ex-smokers using no NRT had significantly lower cotinine values at follow-up than all 237 
other groups (Table 2). Adjusted analysis confirmed these group differences (Wald χ2 (3)=78.9, p<0.001) 238 
and showed baseline nicotine dependence as the only additional significant predictor of follow-up cotinine 239 
levels (Wald χ2 (1)=15.4, p<0.001). There were no group differences in follow-up alpha-amylase levels 240 
which was confirmed in adjusted analysis (Table 2); only greater nicotine dependence at baseline was 241 
positively associated with follow-up alpha-amylase activity (Wald χ2 (1)=8.1, p=0.004). 242 
 243 
In addition to the cross-sectional analyses for baseline and follow-up data reported above, we also 244 
examined within-person changes from baseline to follow-up in longitudinal analysis (please note that this 245 
group is slightly smaller as not all participants who provided both baseline and follow-up saliva samples had 246 
provided either two samples at each time point or samples that were viable). As shown in Figure 2A, 247 
cotinine levels significantly reduced from baseline to follow-up only in ex-smokers not using NRT at 248 
follow-up (Standardized Z=-9.9, p<0.001) and not in other groups. Adjusted analysis confirmed the 249 
significant NRT use by smoking status interaction for changes in cotinine levels (Wald χ2 (1)=13.0, 250 
p<0.001) and also showed that greater baseline age (Wald χ2 (1)=4.3, p=0.037) and dependence (Wald χ2 251 
(1)=44.8, p<0.001) were associated with an increase in cotinine levels.  252 
 253 
While unadjusted analysis indicated that there was an increase in alpha-amylase activity from 254 
baseline to follow-up in ex-smokers not using NRT at follow-up (Standardized Z=3.0, p=0.003) and not in 255 
other groups (Figure 2B), this was not confirmed in adjusted analysis. Neither the NRT use by smoking 256 
status interaction for changes in alpha-amylase levels (Wald χ2 (1)=2.1, p=0.147) nor main effects for NRT 257 
use (Wald χ2 (1)=0.9, p=0.352) or smoking status (Wald χ2 (1)=0.8, p=0.373) were significant. However, 258 
greater baseline age (Wald χ2 (1)=4.4, p<0.036), dependence (Wald χ2 (1)=6.0, p=0.014) and reporting any 259 
medical condition at baseline (Wald χ2 (1)=5.8, p=0.016) were independently associated with an increase in 260 
alpha-amylase activity. 261 
262 
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DISCUSSION 263 
Extended use of NRT among SSS clients was relatively prevalent, with over one in five who achieve 264 
short-term abstinence continuing to use it beyond the standard treatment length of three months, but 265 
continued long-term use of NRT by those who achieve long-term abstinence at one year is less common at 266 
just below 10%. Nonetheless, given that one year usage rates were estimated at around 5% among ex-267 
smokers who attend SSS in 2002 35, this suggests that recent policy and licensing changes in favour of harm 268 
reduction 9,10,12 may have had some impact on long-term NRT use among services users. This contrasts with 269 
a lack of change in NRT usage pattern observed in the general population following an earlier relaxation of 270 
NRT licensing in 2005 36. However, the low 4% prevalence of concurrent long-term use of NRT among SSS 271 
clients who had relapsed is similar to figures from the general population suggesting that longer-term NRT 272 
use among smokers is rare 37. Indeed, concurrent NRT use among smokers, either for temporary abstinence 273 
or cutting down, has remained relatively stable since 2002 38, with most smokers using NRT for less than 274 
three months 37. 275 
 276 
Interestingly, despite a steady increase in the prevalence of e-cigarette use among smokers and ex-277 
smokers in the UK 39, the long-term use of e-cigarettes among past SSS clients in this study was surprisingly 278 
low at less than 3% compared with estimates of one in five smokers or recent ex-smokers using e-cigarettes 279 
in the general population 40. However, this may be due to the specificity of the sample selection and the 280 
timing of the study, being conducted around the time of increasing awareness of e-cigarettes in the UK but 281 
before use became widespread amongst smokers and recent quitters 41.  282 
 283 
This study provides some rare insights in the exposure to nicotine associated with long-term dual or 284 
single use of NRT as well as its impact on a biological index of stress, alpha-amylase. Clinical trials suggest 285 
that permanent replacement of cigarettes with NRT among ex-smokers can result in 40% of baseline levels 286 
of nicotine being substituted by nicotine replacement products long-term 42,43. Our findings not only confirm 287 
substantial substitution of nicotine from cigarettes with nicotine from NRT but, given the lack of changes in 288 
ex-smokers using NRT from baseline to follow-up, suggest that virtually all baseline nicotine may be 289 
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replaced by NRT among long-term ex-smokers. This increase in substitution levels compared with previous 290 
work may reflect differences in our sample or changes in the NRT products available. It is unlikely to be the 291 
result of other product use as all ex-smokers were CO verified and participants with concurrent use of other 292 
nicotine delivery devices, i.e. e-cigarettes, were excluded.  293 
 294 
Confirming previous research 5,44, the concurrent use of NRT among smokers did not appear to 295 
increase their nicotine intake. These findings are in agreement with the hypothesis that smokers are very 296 
adept at titrating nicotine levels, with some nicotine otherwise obtained from cigarettes being replaced by 297 
nicotine from NRT 45. However, our results indicate this also applies to ex-smokers, which is consistent with 298 
a strong genetic component in nicotine intake 46 but at odds with clinical 42 and general population studies 6 299 
showing that nicotine substitution from NRT tapers off over time. Behavioural support in SSS includes 300 
detailed instructions on the correct use of NRT 47 which is not available in other settings and may explain 301 
the differential in both NRT effectiveness and associated nicotine intake when used with and without 302 
behavioural support. 303 
 304 
Although it is unlikely that a substantially increased nicotine intake from NRT would be harmful 305 
48,49, it clearly is a concern for some people and a potential barrier to effective use of nicotine products 16. 306 
Our results not only suggest that dual use with NRT does not increased nicotine intake compared with 307 
continued smoking, they also indicate that use of NRT (either with or without concurrent smoking) is not 308 
associated with an increase in a biomarker of stress response, alpha-amylase, used as a proxy here to signal 309 
potential harm. Given observed reductions in stress levels in smokers following cessation 50, it was 310 
surprising not to see any reductions alpha-amylase levels in quitters. However, it should be noted that 311 
tobacco smoke has been shown to acutely inhibit alpha amylase activity 33, which means that the benefit of 312 
smoking cessation may have been masked by the impact of baseline smoking. Moreover, spot sampling may 313 
not be reliable enough to pick up true long-term changes. While there was an expected association of 314 
increased biological stress with older age and having a medical condition, the association of increased alpha-315 
amylase activity with greater baseline nicotine dependence was not predicted and deserves further 316 
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investigation. Altogether, these findings are consistent with the view that long-term NRT use is safe and not 317 
associated with increased health risks, certainly compared with continued smoking 21. 318 
 319 
This study has a number of limitations. Despite an initial large sample size, drop out across the study 320 
was inevitably substantial, resulting in relatively few clients with complete baseline and follow-up data on 321 
biomarkers. In addition, the baseline sample differed from the sample followed up. However, differences 322 
were relatively modest, and prevalence data were weighted to account for differential drop out. As clients 323 
self-selected into groups rather than being experimentally assigned, we cannot exclude potential reverse 324 
causation, e.g. particular individuals who happen to have a high sensitivity to nicotine intake may use NRT 325 
for longer. Moreover, we were only able to assess current NRT use but not frequency of NRT use at follow-326 
up which means that it is difficult to ascertain how comparable NRT use was across relapsers and quitters. 327 
However, this study reflects real-world use of NRT and the longitudinal within-group design reduced 328 
confounding by allowed participants to be their own control. Lastly, different methodologies were used to 329 
collect follow-up saliva samples which may have impacted results. However, the same clear instructions 330 
were provided to participants and researchers who for postal and face-to-face collection, respectively. All 331 
assessments were carried out with established, ecologically valid measures and smoking status verified, but 332 
further research would benefit from measuring a wider array of biomarkers of smoking-related harm, 333 
including different biomarkers of chronic stress such as cortisol. 334 
 335 
In conclusion, among former SSS clients long-term NRT use by ex-smokers is relatively rare but 336 
more common than use by smokers. Furthermore, long-term use seems to have increased since the 337 
introduction of harm reduction guidance in the UK. Long-term use of NRT does not appear to have a 338 
detrimental effect on chronic stress response among smokers or ex-smokers and does not increase overall 339 
nicotine intake in smokers but is associated with continuing nicotine intake in ex-smokers, comparable to 340 
when they were smoking.341 
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TABLES AND FIGURES 486 
Table 1: Baseline characteristics 487 
 
Questionnaire data Biomarker data 
Available 
(N=1,047) 
Lost to follow-up 
(N=681) 
Available 
(N=258) 
Lost to follow-up 
(N=454) 
Socio-demographic/health 
characteristics  
  
 
Mean (SD) Age 46.4 (14.0) 41.1 (13.7)‡ 45.7 (13.4) 42.2 (14.6) † 
% (N) Female 55.0 (576) 53.6 (365) 51.6 (133) 48.7 (221) 
% (N) White 97.2 (1018) 94.7 (645)† 96.5 (249) 93.8 (426) 
% (N) Cohabiting 53.4 (559) 47.3 (322)* 53.9 (139) 44.9 (204)* 
% (N) Routine/manual 
occupation 
30.9 (323) 34.5 (235) 25.2 (65) 30.6 (139) 
% (N) Degree or equivalent 10.6 (111) 10.4 (71) 10.5 (27) 9.3 (42) 
% (N) Medical condition 59.5 (622) 52.9 (360)† 57.4 (148) 58.4 (265) 
Smoking characteristics 
 
   
Mean (SD) Heaviness of 
smoking index 
3.28(1.45) 3.22 (1.46) 3.19 (1.54) 3.51 (1.41)† 
% (N) Smoking length < 10 
years 
10.9 (114) 17.4 (118)‡ 9.3 (24) 14.3 (65) 
% (N) Quit attempt last 12 
months 
41.7 (434) 41.0 (275) 38.1 (98) 38.4 (172) 
NHS SSS treatment 
characteristics  
   
% (N) Intervention type 
 Closed group 
 Open (rolling) group 
 Drop-in clinic 
 One to one support 
 Other 
 
3.2 (34) 
20.8 (218) 
26.5 (277) 
49.2 (515) 
0.3 (3) 
  
2.9 (20) 
17.6 (120) 
27.2 (185) 
51.9 (353) 
0.3 (2) 
 
6.6 (17) 
21.3 (55) 
24.4 (63) 
47.7 (123) 
0 (0) 
 * 
4.6 (21) 
13.9 (63) 
30.4 (138) 
50.7 (230) 
0.4 (2) 
% (N) Medication 
 Single NRT 
 Combination NRT 
 Varenicline 
 Other‖ 
 None 
 
17.4 (182) 
12.2 (128) 
50.2 (526) 
19.0 (199) 
1.1 (12) 
  
17.9 (122) 
15.1 (103) 
48.5 (330) 
17.0 (116) 
1.5 (10) 
 
17.4 (45) 
16.3 (42) 
48.4 (125) 
16.3 (42) 
1.6 (4) 
 † 
15.2 (69) 
27.3 (124) 
37.4 (170) 
19.2 (87) 
0.9 (4) 
*p<0.05; †p<0.01; ‡<0.001; ‖Bupropion and mixed medication (mainly NRT) 488 
489 
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Table 2: Biomarker results by follow-up NRT use and follow-up smoking status 490 
 
Smokers (relapsers) Ex-smokers (quitters) 
NRT use (N=18) No NRT use (N=73) NRT use (N=14) 
No NRT use 
(N=153) 
Baseline assessment 
 
  
 
Geometric Mean (IQR/n) 
Cotinine in ng/mL 
193.7 (323.1/17) 241.1 (238.8/68) 340.1 (163.9/13) 197.6 (174.6/146) 
Geometric Mean (IQR/n) 
Alpha-amylase in U/mL 
20.1 (59.1/12) 21.8 (27.2/45) 29.1 (14.2/11) 23.6 (30.5/109) 
Follow-up assessment     
Geometric Mean (IQR/n) 
Cotinine in ng/ml 
210.8 (240.0/16)a 244.7 (198.7/69)a 169.9 (449.6/10)a 1.2 (21.6/149)b 
Geometric Mean (IQR/n) 
Alpha-amylase in U/mL 
25.8 (69.6/13) 26.7 (32.2/43) 22.4 (49.7/10) 27.6 (37.7/111) 
a,bDifferent letters indicate significant differences between groups(p<0.05); IQR-Interquartile Range491 
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Figure legends 492 
Figure 1: (A) NRT use across follow-up period among those who had used NRT during initial quit attempt 493 
(N=583)*; (B) Product type used among those with long-term NRT use at follow-up (N=50) 494 
*Includes e-cigarettes (users of products at 12-month provide denominator for Figure 1B); †No use of 495 
nicotine nasal spray reported at 12-month follow-up; users could indicate multiple products; Error bars are 496 
95% confidence intervals 497 
 498 
Figure 2: Change in (A) cotinine levels (N=232) and (B) alpha-amylase activity (N=166) from baseline to 499 
follow-up as a function of NRT use and smoking status at follow-up 500 
Data not available from N participants due to insufficient samples or contamination: *26 cases; †92 cases; 501 
Error bars are interquartile range 502 
503 
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Figure 1: 504 
 505 
506 
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Figure 2: 507 
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